ASND vs. GH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ASND and GH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ASND’s market capitalization of 10.52 billion USD is substantially larger than GH’s 6.26 billion USD, indicating a significant difference in their market valuations.
GH carries a higher beta at 1.38, indicating it’s more sensitive to market moves, while ASND (beta: 0.36) exhibits greater stability.
ASND trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, GH is a standard domestic listing.
| Symbol | ASND | GH |
|---|---|---|
| Company Name | Ascendis Pharma A/S | Guardant Health, Inc. |
| Country | DK | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Diagnostics & Research |
| CEO | Jan Moller Mikkelsen | Helmy Eltoukhy |
| Price | 174.18 USD | 50.5 USD |
| Market Cap | 10.52 billion USD | 6.26 billion USD |
| Beta | 0.36 | 1.38 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 28, 2015 | October 4, 2018 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ASND and GH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ASND
191.42%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ASND’s Return on Equity of 191.42% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
GH
368.51%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
GH’s Return on Equity of 368.51% is exceptionally high, placing it well beyond the typical range for the Medical - Diagnostics & Research industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
ASND
-50.64%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ASND has a negative Return on Invested Capital of -50.64%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
GH
-40.79%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
GH has a negative Return on Invested Capital of -40.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
ASND
-92.67%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ASND has a negative Net Profit Margin of -92.67%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
GH
-53.82%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
GH has a negative Net Profit Margin of -53.82%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
ASND
-90.54%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ASND has a negative Operating Profit Margin of -90.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
GH
-58.78%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
GH has a negative Operating Profit Margin of -58.78%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ASND | GH |
|---|---|---|
| Return on Equity (TTM) | 191.42% | 368.51% |
| Return on Assets (TTM) | -32.19% | -30.99% |
| Return on Invested Capital (TTM) | -50.64% | -40.79% |
| Net Profit Margin (TTM) | -92.67% | -53.82% |
| Operating Profit Margin (TTM) | -90.54% | -58.78% |
| Gross Profit Margin (TTM) | 85.30% | 61.34% |
Financial Strength
Current Ratio
ASND
1.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ASND’s Current Ratio of 1.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
GH
4.11
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
GH’s Current Ratio of 4.11 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ASND
-4.46
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
ASND has a Debt-to-Equity Ratio of -4.46, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
GH
-5.21
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
GH has a Debt-to-Equity Ratio of -5.21, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
Interest Coverage Ratio
ASND
-3.72
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ASND has a negative Interest Coverage Ratio of -3.72. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
GH
-166.83
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
GH has a negative Interest Coverage Ratio of -166.83. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ASND | GH |
|---|---|---|
| Current Ratio (TTM) | 1.04 | 4.11 |
| Quick Ratio (TTM) | 0.71 | 3.76 |
| Debt-to-Equity Ratio (TTM) | -4.46 | -5.21 |
| Debt-to-Asset Ratio (TTM) | 0.80 | 0.97 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.34 | -1.53 |
| Interest Coverage Ratio (TTM) | -3.72 | -166.83 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ASND and GH. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
GH
0.00%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
GH
0.00%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ASND | GH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ASND
-25.98
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ASND has a negative P/E Ratio of -25.98. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
GH
-15.02
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
GH has a negative P/E Ratio of -15.02. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
ASND
-2.36
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ASND has a negative Forward PEG Ratio of -2.36. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
GH
0.63
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
GH’s Forward PEG Ratio of 0.63 is within the middle range of its peers in the Medical - Diagnostics & Research industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ASND
24.22
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ASND’s P/S Ratio of 24.22 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
GH
8.08
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
GH’s P/S Ratio of 8.08 is in the upper echelon for the Medical - Diagnostics & Research industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
ASND
-46.77
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
GH
-24.94
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | ASND | GH |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -25.98 | -15.02 |
| Forward PEG Ratio (TTM) | -2.36 | 0.63 |
| Price-to-Sales Ratio (P/S, TTM) | 24.22 | 8.08 |
| Price-to-Book Ratio (P/B, TTM) | -46.77 | -24.94 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -29.03 | -20.52 |
| EV-to-EBITDA (TTM) | -37.74 | -17.25 |
| EV-to-Sales (TTM) | 25.11 | 8.87 |